letermovir
Sign in to saveLetermovir (INN; brand name Prevymis) is an antiviral drug for the prevention of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections. The drug was initially developed by the anti-infective division at Bayer, which became AiCuris Anti-infective Cures AG through a spin-out and progressed the development to end of Phase 2 before the project was sold to Merck & Co for Phase 3 development and approval.
Key facts
- Drug.image
- Letermovir skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Prevymis
- Drug.MedlinePlus
- a618006
- Drug.DailyMedID
- Letermovir
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AX18
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 37% (estimate)
- Drug.protein_bound
- 98.2%
- Drug.metabolism
- glucuronidation (UGT1A1/1A3) to a minor extent
- Drug.elimination_half life
- 12 hours
- Drug.excretion
- 93.3% via feces, <2% via kidneys
via Wikipedia infobox
Article
10 sectionsContents
- Medical use
- Contraindications
- Adverse effects
- Overdose
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- References
- External links
{{Infobox drug | image = Letermovir skeletal.svg | image_class = skin-invert-image | alt = | caption =
| tradename = Prevymis | Drugs.com = | MedlinePlus = a618006 | DailyMedID = Letermovir | pregnancy_AU = B3 | pregnancy_category= | routes_of_administration = By mouth, intravenous | ATC_prefix = J05 | ATC_suffix = AX18